Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,775 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04985825 | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(I-PACE) | withdrawn | Phase 2 | 0 | Pega-One S.A.S.INDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT03353181 | Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar Biliary Strictures(ENBD) | withdrawn | N/A | 0 | Changhai HospitalOTHER | 1 | Aug 25, 2022 |
| NCT04200066 | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | University of RochesterOTHER | 0 | Aug 22, 2022 | clinicaltrials |
| NCT04406207 | Endogenous Retroviruses in Acute Myeloid Leukemia(ERVAL) | withdrawn | — | 0 | Hospices Civils de LyonOTHER | 0 | Aug 22, 2022 | clinicaltrials |
| NCT05395260 | FL- 101 Study in Non-Metastatic MIBC | withdrawn | Early Phase 1 | 0 | Flame BiosciencesINDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT01769885 | Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Aug 15, 2022 | clinicaltrials |
| NCT04926168 | 6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM) | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 10, 2022 | clinicaltrials |
| NCT04972253 | Phase I BLASST-3 Trial((BLASST)-3) | withdrawn | Phase 1 | 0 | Guru P. SonpavdeOTHER | 0 | Aug 10, 2022 | clinicaltrials |
| NCT04807478 | Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC) | withdrawn | — | 0 | Fresenius KabiINDUSTRY | 0 | Aug 4, 2022 | clinicaltrials |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Aug 4, 2022 | clinicaltrials |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT04775056 | A Study to Evaluate Vaccines Against COVID-19 in the Real World | withdrawn | — | 0 | Humanity & Health Medical Group LimitedOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT04349111 | An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | withdrawn | N/A | 0 | Xoft, Inc.INDUSTRY | 0 | Aug 2, 2022 | clinicaltrials |
| NCT05263609 | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04371458 | Thymectomy With and Without Povidone-iodine Pleural Lavage in Stage IVA Thymic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Yale UniversityOTHER | 0 | Jul 25, 2022 | clinicaltrials |
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT04306861 | Novel MRI Techniques for Pancreatic Cancer | withdrawn | — | 0 | Beth Israel Deaconess Medical CenterOTHER | 0 | Jul 21, 2022 | clinicaltrials |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Jul 18, 2022 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 | clinicaltrials |
| NCT03754140 | Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases(INTRANS) | withdrawn | Phase 2 | 0 | Melanoma Institute AustraliaOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT04717687 | Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma(HOPE) | withdrawn | N/A | 0 | Poitiers University HospitalOTHER | 0 | Jul 13, 2022 | clinicaltrials |
| NCT04354727 | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05227131 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer(MARGARET) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | Jul 11, 2022 | clinicaltrials |
| NCT04802031 | Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Thomas Martin, MDOTHER | 0 | Jul 7, 2022 | clinicaltrials |
| NCT04849377 | RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | withdrawn | Phase 2 | 0 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT04467281 | A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases(TOPAZ) | withdrawn | Phase 1 / Phase 2 | 0 | Reva BashoOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | withdrawn | Phase 1 / Phase 2 | 0 | Lion TCR Pte. Ltd.INDUSTRY | 2 | Jun 30, 2022 | clinicaltrials |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Walid Shaib, MDOTHER | 0 | Jun 29, 2022 | clinicaltrials |
| NCT04138875 | A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT05160064 | Long-term Registry of Patients Treated With Loncastuximab Tesirine | withdrawn | — | 0 | ADC Therapeutics S.A.INDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT01371240 | Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity | withdrawn | Early Phase 1 | 0 | University Hospitals Cleveland Medical CenterOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT03841565 | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 0 | Jun 15, 2022 | clinicaltrials |
| NCT05279859 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies(HERKULES-4) | withdrawn | Phase 1 / Phase 2 | 0 | Erasca, Inc.INDUSTRY | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04560439 | Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT04655391 | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT04961320 | Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT05244434 | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT04836832 | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | withdrawn | Phase 1 | 0 | Narendranath EpperlaOTHER | 0 | Jun 7, 2022 | clinicaltrials |
| NCT03660072 | Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma | withdrawn | — | 0 | Bristol-Myers SquibbINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT05005936 | Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast Ultrasonography in Breast Cancer Treatment Response Assessment | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05022394 | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT04676243 | Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML(Q-SOC) | withdrawn | Phase 3 | 0 | University Hospital HeidelbergOTHER | 0 | May 25, 2022 | clinicaltrials |
| NCT04190498 | Sleep Apnoea Syndrome and Hepatocellular Carcinoma(ECHAPS) | withdrawn | — | 0 | University Hospital, GrenobleOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT04264806 | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) | withdrawn | Phase 2 | 0 | Janssen Research & Development, LLCINDUSTRY | 11 | May 20, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Sep 13, 2022source: clinicaltrials